Evidence map›Paper›PMID 30358104›Full record

ArticleMolecular oncology2019

Circulating pancreatic cancer exosomal RNAs for detection of pancreatic cancer.

Tatsuya Kitagawa, Keisuke Taniuchi, Makiko Tsuboi, Masahiko Sakaguchi, Takuhiro Kohsaki, Takehiro Okabayashi, Toshiji Saibara

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 116 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tatsuya KitagawaDepartment of Gastroenterology and Hepatology, Kochi Medical School, Kochi University, Nankoku, Japan.
Keisuke TaniuchiDepartment of Gastroenterology and Hepatology, Kochi Medical School, Kochi University, Nankoku, Japan.
Makiko TsuboiDepartment of Gastroenterology and Hepatology, Kochi Medical School, Kochi University, Nankoku, Japan.
Masahiko SakaguchiDepartment of Integrated Center for Advanced Medical Technologies, Kochi Medical School, Kochi University, Nankoku, Japan.
Takuhiro KohsakiDepartment of Gastroenterology and Hepatology, Kochi Medical School, Kochi University, Nankoku, Japan.
Takehiro OkabayashiDepartment of Surgery, Kochi Health Sciences Center, Japan.
Toshiji SaibaraDepartment of Gastroenterology and Hepatology, Kochi Medical School, Kochi University, Nankoku, Japan.
Kōchi University · JPKochi Medical School Hospital · JP

Funding

Grants-in-Aid for Scientific Research 15K14396Grants-in-Aid for Scientific Research 16K09397Grants-in-Aid for Scientific Research 17K09463
6 · The paper itself

Abstract

Diagnostic biomarkers for the early diagnosis of pancreatic cancer are needed to improve prognosis for this disease. The aim of this study was to investigate differences in the expression of four messenger RNAs (mRNAs: CCDC88A, ARF6, Vav3, and WASF2) and five small nucleolar RNAs (snoRNAs: SNORA14B, SNORA18, SNORA25, SNORA74A, and SNORD22) in serum of patients with pancreatic cancer and control participants for use in the diagnosis of pancreatic cancer. Results were compared with the expression of sialylated Lewis (a) blood group antigen CA19-9, the standard clinical tumor biomarker. Reverse transcription quantitative real-time PCR showed that all of the mRNAs and snoRNAs, except CCDC88A, were encapsulated in exosomes and secreted from cultured pancreatic cancer cells, and present in cell culture medium. In a discovery-stage clinical study involving 27 pancreatic cancer patients and 13 controls, the area under the receiver operating characteristic curve (AUC) of two mRNAs (WASF2 and ARF6) and two snoRNAs (SNORA74A and SNORA25) was > 0.9 for distinguishing pancreatic cancer patients from controls; the AUC of CA19-9 was 0.897. Comparing serum levels of WASF2, ARF6, SNORA74A, SNORA25, and CA19-9 revealed that levels of WASF2 were the most highly correlated with the risk of pancreatic cancer. The AUCs of WASF2, ARF6, SNORA74A, and SNORA25 in serum from patients in the early stages of pancreatic cancer (stages 0, I, and IIA) were > 0.9, compared with an AUC of 0.93 for the level of CA19-9. The results of this study suggest that WASF2, ARF6, SNORA74A, and SNORA25 may be useful tools for the early detection of pancreatic cancer. Monitoring serum levels of WASF2 mRNA may be particularly useful, as it was the most highly correlated with pancreatic cancer risk.

Indexed as

AdultAgedAged, 80 and overArea Under CurveCA-19-9 AntigenCell Line, TumorExosomesFemaleGene Expression Regulation, NeoplasticHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisPancreatic NeoplasmsRNA, MessengerCA-19-9 AntigenRNA, MessengerRNA, Neoplasmdiagnostic markerexosomepancreatic cancersmall nucleolar RNA

Identifiers

PMID30358104
PMCPMC6360365
OpenAlexW2898404783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.